Novo Nordisk became Europe’s most valuable company with the rise of Wegovy and Ozempic, but it’s facing stiff competition from a local pharma rival

Novo Nordisk faces opposition from local rival, Zealand Pharma. The pharma company has so far risen 63% in market value on the Copenhagen stock exchange this year compared with 40% for its larger peer. Read More